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Objective. To evaluate whether two diﬀerent regimens of weekly injections could lead to similar auxological and metabolic eﬀects in
children with growth hormone deﬁciency (GHD). Design. 32 GHD children (25 males, mean age 10.5 ± 2.2 yr) were randomly
assigned to receive daily (group A, 16 patients) or TIW (group B, 16 patients) GHT for 12 months. Methods. Auxological
parameters, insulin-like growth factor-I (IGF-I), glucose and insulin during OGTT, glycosylated hemoglobin (HbA1c), lipid
proﬁle, the oral disposition index (DIo), the homeostasis model assessment estimate of insulin resistance (Homa-IR), and
the insulin sensitivity index (ISI). Results. After 12 months, both groups showed a signiﬁcant and comparable
improvement in height (p < 0 001) and IGF-I (p < 0 001). As regards the metabolic parameters, in both groups, we found a
signiﬁcant increase in fasting insulin (p < 0 001 and p = 0 026) and Homa-IR (p < 0 001 and p = 0 019). A signiﬁcant increase in
fasting glucose (p = 0 001) and a decrease in ISI (p < 0 001) and DIo (p = 0 002) were only found in group A. Conclusions. The
TIW regimen is eﬀective and comparable with the daily regimen in improving auxological parameters and has a more favorable
metabolic impact in GHD children. This trial is registered with ClinicalTrials.gov NCT03033121.
1. Introduction
Children with acclaimed GH deﬁciency (GHD) should be
treated with recombinant human GH with the primary
objective of the normalization of height and attainment of
normal adult stature. In addition, the metabolic and body
composition beneﬁts should always be considered. Long-
term GHT should theoretically mimic the complex physio-
logical pattern of GH release, which is unlikely to be
achieved with the current modes of administration. From
1960, GH treatment (GHT) in hypopituitary children was
restricted for many years to three injections per week
(TIW), because it was convenient and eﬃcacious [1]. The
availability of recombinant GH has enabled larger scale
use of GHT on a daily basis. Indeed, daily subcutaneous
injections were found to be more eﬀective for children
and this daily format was introduced as a routine treatment
regimen during the 1980s [2]. Currently, GHT in GHD
patients is commonly administered in daily injections [3],
but this modality of treatment is not complied with by
the totality of patients. In addition, it should be considered
that physiological spontaneous pulsatile GH secretion can-
not be reproduced by either TIW or daily injections and
that a perfect physiological regimen has not been identiﬁed.
The role played by GH pulsatility on both growth and
metabolism is important, although it is not known whether
closer imitation of the endogenous GH secretory pattern
would improve the response to GHT [4]. For these reasons,
eﬀorts have been made to make GHT more similar to phys-
iological GH secretion and long-acting forms of recombi-
nant human GH with a more convenient dosing regimen
are under development for children and adults [5–7].
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In addition, the eﬀectiveness of any therapy is contingent
on patient adherence and the reported levels of nonadher-
ence to GHT in children are highly variable, leading to
reduced eﬃcacy and increased health care costs [8–11]. Since
one of the main factors associated with poor adherence to
GHT is the complex treatment regimen, reduced frequency
of the administration of medication is generally associated
with better adherence [12]. The clinical outcomes of daily
versus TIW GH administration were already studied many
years ago. The TIW regimen seems to produce similar eﬀects
to those of daily injections in both adults and children with
GHD [13–15], although several studies have reported that
the daily GH administration in children was more eﬀective
than TIW dosing on linear growth [16, 17]. However, to date,
the metabolic eﬀects of GHT given in an alternative regimen
in GHD patients have only been evaluated in adults and
never in children. This study aimed to reevaluate whether
the same weekly dose of GH given by two diﬀerent regimens
of weekly injections could lead to similar auxological and
especially metabolic eﬀects in children with GHD.
2. Subjects and Methods
Thirty-two prepubertal children (25 males, 7 females; mean
age 9.5± 2.2 years) with a diagnosis of isolated idiopathic
GHD were consecutively enrolled in this prospective ran-
domized clinical study over a period going from January
2015 to December 2015 from the Section of Endocrinology,
University of Palermo (www.ClinicalTrials.gov, identiﬁca-
tion number NCT03033121).
All subjects and their parents gave informed written con-
sent to the study. The diagnosis of GHD was established by
the clinical, auxological, radiological, and biochemical cri-
teria of the GH Research Society [3].
As auxological data, we considered the height and growth
velocity 1 year before diagnosis. As radiological criteria, we
considered a bone age delay, estimated from an X-ray of
the left wrist and hand and evaluated according to the
methods of Greulich and Pyle, of at least 1 year with respect
to the chronological age [18]. Subsequently, we calculated the
bone/chronological age ratio.
Biochemically, GHD was demonstrated by the failure of
GH to respond to the two stimuli (arginine and glucagon
test) with GH peaks below 8μg/L. We excluded children
aﬀected by multiple pituitary hormone deﬁciency or receiv-
ing any other kind of hormonal replacement therapy or drug
and GHD children treated for less than 12 months. All chil-
dren, including older ones, were in the ﬁrst stage of sexual
development according to the Marshall and Tanner criteria
[19] to avoid any interference of puberty on auxological
and metabolic parameters, and they maintained the prepu-
bertal hormonal status during the 12 months of follow-up.
Neuroimaging, with magnetic resonance imaging of the
hypothalamic-pituitary region, was arbitrarily performed in
GHD children with more severe GHD, that is, with GH
peak≤3μg/L (13 children). No evidence of intrasellar lesions
was found, while 5 children showed pituitary hypoplasia.
Enrolled patients were consecutively and randomly
assigned by using the balance block randomization method
in a 1 : 1 ratio to two diﬀerent GHT regimen, given in the eve-
ning: group A included 16 children (12 males, 4 females,
mean age 9.8± 2.2 years) receiving daily GH injections, and
group B included 16 children (13 males, 3 females, mean
age 9.3± 2.2 years) receiving TIW of GH.
All children were naïve to GHT. In line with our internal
protocol, in all children, we used a weight-based GH treat-
ment [20]. Regardless of GH peak, we used the same initial
weekly dose of 0.175mg/kg (corresponding to the daily dose
of 0.025mg/kg) of GH with a gradual increase every 6
months in order to maintain the IGF-I levels constantly in
the normal range. In detail, from months 1 to 6, we used
the mean weekly dose of 0.175mg/kg and from months 6
to 12, the mean weekly dose of 0.20mg/kg.
Four children (3 males, 1 female; 2 from group A and 2
from group B, resp.) who changed pubertal stage (from the
ﬁrst to the second stage) during the follow-up were excluded
from the study.
2.1. Study Design. In all patients, at baseline and after 12
months of GHT, we measured the body height (standard
deviation, SD), body mass index (BMI), and waist circumfer-
ence (WC). The height and BMI were expressed as SD due to
the wide age range of patients.
Blood samples were drawn after an overnight fast. Labo-
ratory assessment included fasting glucose and insulin levels,
insulin-like growth factor-I (IGF-I), glycosylated hemoglobin
(HbA1c), lipid proﬁle including total cholesterol, high-
density cholesterol (HDL), and triglycerides. Low-density
lipoprotein (LDL) cholesterol levels were evaluated by the
following formula: total cholesterol− (HDL cholesterol− tri-
glycerides/5). This sample also served as the baseline sample
for an oral glucose tolerance test (OGTT). Blood samples
were collected every 30min for 2 h for glucose and insulin
measurements. At 12 months, in group B, all samples were
drawn the morning after the GH dose was received.
The estimation of the basal insulin secretion included
fasting insulin levels, while the oral disposition index (DIo)
was used as an index of the ability of the β-cell to regulate
its insulin response to stimuli based on the diﬀerences in
insulin sensitivity. DIo was calculated at the times 0′and 30′
during OGTT as described [21]. As surrogate estimates of
insulin sensitivity, we considered the homeostasis model
assessment estimate of insulin resistance (Homa-IR) [22]
and the insulin sensitivity index (ISI), a composite index
derived from the OGTT and validated by Matsuda and
DeFronzo [23].
The institutional Ethics Committee of the University of
Palermo approved this study. At the time of hospitalization,
a written informed consent for the scientiﬁc use of the data
was obtained from all the participants’ parents.
2.2. Hormone and Biochemical Assays. All biochemical data
were collected after an overnight fasting. Glucose, HbA1c,
and lipids were measured in the centralized accredited labo-
ratories of the University of Palermo with the standard
methods. Serum insulin was measured by ELISA (DRG
Instruments GmbH, Germany). The sensitivity of the
method was 1 IU/mL. The normal insulin range (IU/mL)
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was 5–19. Throughout the follow-up, serum GH levels
were measured by immunoradiometric assay using com-
mercially available kits (Radim, Italy). The sensitivity of
the assay was 0.04μg/L. The intra- and interassay coeﬃ-
cients of variation (CVs) were 2.5–3.9 and 3.8–5.0%,
respectively. We reported GH concentrations in μg/L of
IS 98/574.
IGF-I levels were measured by a chemiluminescent
immunometric assay (Immulite 2000; Diagnostic Products
Corp., Los Angeles, CA) using murine monoclonal anti-
IGF-I antibodies. The standards were calibrated against the
World Health Organization second IS 87/518. The assay
had an analytical sensitivity of 1.9μg/L. The intra- and inter-
assay CVs were 2.3–3.9% and 3.7-8.1%, respectively.
2.3. Statistical Analysis. The Statistical Packages for Social
Sciences (SPSS) version 17 was used for data analysis.
Baseline characteristics were presented as mean± standard
deviation (SD); rates and proportions were calculated for
categorical data. The normality of distribution of the
quantitative variables was assessed with the Kolmogorov-
Smirnov test. The diﬀerences between groups were eval-
uated by the Student t-test. A p value of <0.05 was
considered statistically signiﬁcant.
3. Results
The baseline clinical and biochemical features of children,
grouped according to the diﬀerent GHT regimens, are shown
in Table 1.
No diﬀerence was found for chronological age (9.8± 2.2
versus 9.3± 2.2 years; p = 0 553), height (−2.06± 0.43 ver-
sus −2.04± 0.69 SD; p = 0 332), growth velocity (−3.4
± 0.9 versus −3.3± 0.9 SD; p = 0 418), BMI (−0.46± 0.48
versus −0.79± 0.45 SD; p = 0 418), WC (60.5± 10.4 versus
60.1± 9.0 cm; p = 0 828), and bone age delay (0.81± 0.12
versus 0.81± 0.09; p = 0 053) between groups A and B.
Similarly, the 2 groups of children showed similar IGF-I
levels (99.5± 23.8 versus 100± 23.4μg/L) and GH peak after
arginine (5.08± 2.54 versus 3.28± 2.49μg/L; p = 0 062) and
glucagon test (3.22μg/L± 1.96μg/L versus 4.77μg/L
± 3.31μg/L; p = 0 119).
After 12 months of treatment, both groups of chil-
dren showed a signiﬁcant increase in height (−1.5± 0.40
versus −2.06± 0.43 SD and −1.5± 0.5 versus −2.04± 0.69
SD; both p < 0 001), growth velocity (2.7± 0.7 versus
−3.4± 0.9 SD; p = 0 003 and 3± 1.4 versus −3.3± 0.9
SD; p < 0 001), and IGF-I levels (332± 125 versus 99.5
± 23.8μg/L and 352± 89.1 versus 100± 23.4μg/L; both
p < 0 001), with a concomitant lower, although not statis-
tically signiﬁcant, bone age delay (0.90± 0.05 versus 0.81
± 0.12; p = 0 089 and 0.89± 0.11 versus 0.81± 0.09;
p = 0 098), while no signiﬁcant diﬀerence was found in
BMI and WC (Table 1).
As regards the metabolic parameters, no diﬀerence was
found in baseline parameters between the 2 groups
Table 1: Clinical and biochemical features of patients grouped according to the GH treatment regimen (group A and group B) at baseline and
after 12 months of treatment.
7 doses per week
(group A)
16 patients
baseline
7 doses per week
(group A)
16 patients
12 months
3 doses per week
(group B)
16 patients
baseline
3 doses per week
(group B)
16 patients
12 months
Mean± SD Mean± SD p Mean± SD Mean± SD p
Height (SD) −2.06± 0.43 −1.5± 0.40 <0.001 −2.04± 0.69 −1.5± 0.5 <0.001
BMI (SD) −0.46± 0.48 −0.45± 1.3 0.876 −0.79± 0.45 −0.86± 0.8 0.052
Waist circumference (cm) 60.5± 10.4 62± 10 0.317 60.1± 9.0 61.5± 7.0 0.463
Growth velocity (SD) −3.4± 0.9 2.7± 1.7 0.003 −3.3± 0.9 3± 1.4 <0.001
Bone/chronological age ratio 0.81± 0.12 0.90± 0.05 0.089 0.81± 0.09 0.89± 0.11 0.098
IGF-I (μg/L) 99.5± 23.8 332± 125 <0.001 100± 23.4 352± 89.1 <0.001
SD: standard deviation; BMI: body mass index.
Table 2: Diﬀerence in metabolic parameters between patients
grouped according to the GH treatment regimen (group A and
group B) at baseline.
7 doses per week
(group A)
16 patients
3 doses per week
(group B)
16 patients
Mean± SD Mean± SD p
Fasting glucose
(mmol/L)
4± 0.65 4.17± 0.45 0.801
Fasting insulin
(IU/mL)
2.9± 2.2 2.8± 2.2 0.687
HbA1c (%) 5.1± 0.3 5.3± 0.3 0.108
Homa-IR 0.52± 0.41 0.53± 0.41 0.688
ISI-Matsuda 9.65± 0.82 9.03± 1.63 0.186
DIo 4.48± 1.81 4.68± 1.39 0.548
Total cholesterol
(mmol/L)
4.12± 0.76 3.98± 0.51 0.130
HDL cholesterol
(mmol/L)
1.58± 0.44 1.65± 0.31 0.563
LDL cholesterol
(mmol/L)
2.84± 0.53 2.11± 0.36 0.063
Triglycerides
(mmol/L)
1.50± 0.41 1.38± 0.52 0.942
BMI: body mass index; DIo: oral disposition index.
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(Table 2). After 12 months of treatment in both groups, we
found a signiﬁcant increase in fasting insulin (9.2± 5.4 ver-
sus 2.9± 2.2 IU/mL; p < 0 001 and 5.7± 2.4 versus 2.8
± 2.2 IU/mL; p = 0 026) and Homa-IR (1.98± 1.20 versus
0.52± 0.41 IU/mL; p < 0 001 and 1.16± 0.53 versus 0.53
± 0.41; p = 0 019). A signiﬁcant increase in fasting glucose
(4.77± 0.39 versus 4± 0.65mmol/L; p = 0 001) with a con-
comitant decrease in ISI-Matsuda (8.59± 0.83 versus 9.65
± 0.82; p < 0 001) and DIo (2.46± 1.27 versus 4.48± 1.81;
p = 0 002) from baseline to 12 months was only found in
group A (Figure 1; Table 3).
No signiﬁcant changes were found in either group in
HbA1c levels and lipid proﬁle (Table 3).
When we analyzed the change (delta) in clinical and met-
abolic parameters from baseline to 12 months of GHT, we
found a signiﬁcantly greater delta of insulin (p = 0 043),
Homa-IR (p = 0 032), ISI-Matsuda (p < 0 001), and DIo
(p = 0 001) in group A than in group B. The delta in
fasting glucose and HbA1c, although not statistically signiﬁ-
cant, was found to be higher in group A than group B, while
no signiﬁcant diﬀerence was found in clinical parameters and
in other metabolic indexes (Table 4). No side eﬀects were
observed in any child.
4. Discussion
This prospective and controlled study demonstrates that
TIW regimen of GHT has comparable auxological eﬀects to
daily treatment with a more favorable metabolic impact,
leading to a less pronounced worsening in insulin sensitivity
and beta-cell secretion.
It is known that the classical GHT, consisting of a single
daily GH injection, does not correspond to physiological
spontaneous GH secretion and probably leads to continuous
exposure and supraphysiological 24-hour integrated concen-
trations of GH. In addition, GH pulsatility reveals two major
attributes, pulse amplitude and pulse frequency, and several
studies have demonstrated that auxological parameters in
children are mainly modulated by GH pulse amplitude, while
frequency appears to play a smaller role [24, 25]. Clinical
studies that have compared the TIW regimen with the daily
administration of GH in children have always evaluated
almost exclusively the auxological data, although the goal of
GHT is also metabolic. Several studies report that the daily
GH administration was more eﬀective on linear growth than
TIW dosing [2, 14, 16, 17, 26]. These data were conﬁrmed by
MacGillivray et al., who demonstrated greater growth
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Figure 1: Fasting glucose, ISI-Matsuda, and oral disposition index (DIo) of patients grouped according to the GH treatment regimen (7 or 3
doses per week) at baseline and after 12 months of treatment.
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velocity in prepubertal naïve GHD children after 4 years of
GHT given daily rather than thrice weekly [27]. In our study,
in line with previous studies, we found comparable auxologi-
cal eﬀects with the two GHT regimens, since all children
showed a signiﬁcant increase in height and growth velocity,
without any diﬀerence in the delta of these parameters from
baseline to 12 months of GHT in the two groups of children.
These results are in agreement with the study of Smith et al.,
who demonstrated no diﬀerence in auxological parameters
after 12 months of GHT in GHD children receiving GH three
or six days a week or twice daily six days a week, assessing the
main role played by the GH dose and not by the regimen of
administration [14]. Similar results were shown a few years
later by Cavallo et al., who observed no diﬀerence in auxolo-
gical parameters during the 3 times/week treatment schedule
started during the follow-up in already treated GHD children
compared to the previous 6 times/week schedule [15]. The
comparable auxological eﬀect of the 2 regimens of GHT has
also been demonstrated in patients with Turner syndrome
randomized to 3 or 6 times weekly GHT [28]. In addition
to auxological parameters, in our study after 12 months of
GHT, IGF-I levels were shown to be similarly normalized
Table 4: Change (delta) in clinical and metabolic parameters from baseline to 12 months of GH treatment of patients grouped according to
the GH treatment regimen.
7 doses per week
(group A) 16 patients
3 doses per week
(group B) 16 patients
Mean± SD Mean± SD p
Delta height (SD) 0.5± 0.3 0.5± 0.2 0.926
Delta BMI (SD) 0.03± 0.6 −0.4± 0.6 0.109
Delta waist circumference (cm) 1.4± 4.4 1.4± 4.8 0.223
Delta growth velocity (SD) 5.2± 1.7 6.3± 2.7 0.945
Delta IGF-I (μg/L) 220.5± 112.7 204.8± 70.9 0.210
Delta fasting glucose (mmol/L) 0.78± 0.76 0.34± 0.32 0.175
Delta fasting insulin (IU/mL) 6.3± 4.2 2.9± 3.4 0.043
Delta HbA1c (%) 0.07± 0.1 −0.05± 0.1 0.078
Delta Homa-IR 1.46± 0.99 0.63± 0.70 0.032
Delta ISI-Matsuda −1.06± 0.43 −0.21± 0.19 <0.001
Delta DIo −1.31± 0.97 −0.37± 0.34 0.001
Delta total cholesterol (mmol/L) 0.06± 0.01 0.08± 0.05 0.941
Delta HDL cholesterol (mmol/L) 0.04± 0.03 −0.12± 0.04 0.209
Delta LDL cholesterol (mmol/L) 0.01± 0.01 0.15± 0.04 0.498
Delta triglycerides (mmol/L) 0.04± 0.03 0.13± 0.05 0.392
BMI: body mass index; DIo: oral disposition index.
Table 3: Metabolic parameters of patients grouped according to the GH treatment regimen (group A and group B) at baseline and after 12
months of treatment.
7 doses per week
(group A)
16 patients
baseline
7 doses per week
(group A)
16 patients
12 months
3 doses per week
(group B)
16 patients
baseline
3 doses per week
(group B)
16 patients
12 months
Mean± SD Mean± SD p Mean± SD Mean± SD p
Fasting glucose (mmol/L) 4± 0.65 4.77± 0.39 0.001 4.17± 0.45 4.51± 0.35 0.181
Fasting insulin (IU/mL) 2.9± 2.2 9.2± 5.4 <0.001 2.8± 2.2 5.7± 2.4 0.026
HbA1c (%) 5.1± 0.3 5.2± 0.3 0.072 5.3± 0.3 5.2± 0.2 0.189
Homa-IR 0.52± 0.41 1.98± 1.20 <0.001 0.53± 0.41 1.16± 0.53 0.019
ISI-Matsuda 9.65± 0.82 8.59± 0.83 <0.001 9.03± 1.63 8.81± 1.57 0.095
DIo 4.48± 1.81 2.46± 1.27 0.001 4.68± 1.39 4.49± 1.30 0.057
Total cholesterol (mmol/L) 4.12± 0.76 4.07± 0.78 0.521 3.98± 0.51 3.87± 0.58 0.679
HDL cholesterol (mmol/L) 1.58± 0.44 1.54± 0.44 0.489 1.65± 0.31 1.86± 0.45 0.094
LDL cholesterol (mmol/L) 2.84± 0.53 2.84± 0.55 0.961 2.11± 0.36 1.95± 0.61 0.298
Triglycerides (mmol/L) 1.50± 0.41 1.54± 0.61 0.760 1.38± 0.52 1.22± 0.30 0.206
DIo: oral disposition index.
5International Journal of Endocrinology
in both groups, in line with other studies [29, 30], and they
reinforce the idea of the noninferior clinical eﬃcacy of TIW
treatment compared to daily treatment.
Conversely, the metabolic eﬀects of GHT given in an
alternative regimen have been evaluated in adult patients
and never in children. It is well known that severe GHD in
children is associated with signiﬁcant impairment of body
composition and an adverse metabolic proﬁle [31], as well
as in adults [32].
Amato et al. showed that GHT with TIW regimen in
adult GHD patients is eﬀective in improving metabolic
parameters, with an eﬃcacy comparable to that observed in
patients treated with daily GHT [29], and these data are in
agreement with those of Giavoli et al. [33]. Reinforcing these
ﬁndings, Pincelli et al. demonstrated that a TIW regimen of
GHT is able to reverse cardiovascular abnormalities in addi-
tion to improving body composition and lipid proﬁle in adult
patients [34].
Substantially, our data demonstrated that all children,
regardless of GHT regimen, showed a worsening in insulin
sensitivity after 12 months of treatment, as demonstrated
by the increase in Homa-IR, already shown in adult
patients [33]. This eﬀect of the GHT is well known.
Indeed, given the insulin antagonistic action of GH in
addition to the direct stimulatory eﬀect on β-cell, GHT
can lead to glucose metabolism impairment through a
decrease in insulin sensitivity and an impairment of pan-
creatic β-cell function [35]. We previously demonstrated
an increase in Homa-IR, related to the increased insulin
levels, in GHD children after GHT [36, 37], and a degree
of impairment of glucose metabolism during GHT has
often been previously demonstrated [38]. However, the
limit of the evaluation of the insulin sensitivity and secre-
tion performed through insulin-derived indexes [39] is
always to be taken into account.
As regards the change in glucose levels during GHT, in
adult GHD patients, Johansson et al. demonstrated lower
blood glucose and insulin levels during a TIW regimen than
during daily injections [40]. The authors explained this result
as due to the concomitant lower serum IGF-I levels, which
may be important for the balanced eﬀect of GH on insulin
sensitivity and glucose metabolism [41].
Our data partially support this study. We only found a
signiﬁcant increase in fasting glucose levels in group A,
despite the concomitant increase in insulin during GHT in
both groups. This result suggests the inability of the β-cells
to adequately compensate the insulin resistance state, as
indicated by the signiﬁcant reduction in DIo and ISI-Mat-
suda, only in group A. This ﬁnding is in agreement with a
previous study that demonstrated inadequate β-cell com-
pensation of decreased insulin sensitivity in GHD children
during GHT [42].
In addition, conﬁrming these data, when the change in
metabolic parameters from baseline to 12 months of GHT
was evaluated and directly compared in the 2 groups of chil-
dren, group A showed a signiﬁcantly greater decrease in insu-
lin sensitivity and β-cell function than group B, with a
concomitant greater increase in fasting glucose, although
not statistically signiﬁcant.
Probably, GHT using daily injections may not be optimal
with respect to glucose metabolism because of the relative
continuous exposure of GH. Furthermore, constant GH
exposure might theoretically downregulate the GH receptor.
Conversely, GHD children treated with the TIW regimen,
because of the relatively short half-life of GH, have lower cir-
culating GH during the “oﬀ” days and the more distinct
peaks of GH could lead to a more favorable metabolic impact.
Indeed, the lower metabolic eﬀects should be advantageous
for insulin sensitivity and, consequently, for fasting glucose
levels, which did not signiﬁcantly increase. However, the sta-
ble Hba1c levels indicate that there was no diﬀerence in long-
term glucose homeostasis between the two regimens of GHT.
This ﬁnding is in agreement with the data of Johansson et al.,
who showed comparable Hba1c levels in GHD adults after 8
weeks of GHT with TIW or daily regimen [40].
In addition, the current study shows no signiﬁcant diﬀer-
ence in lipid proﬁle between the 2 groups of patients, in
agreement with the study of Lucidi et al., who previously
demonstrated that GHT given TIW-induced increments in
protein synthesis and lipolysis comparable to those obtained
after daily treatment GHT in adult patients [30].
On the other hand, GHT given as a TIW regimen could
theoretically result in better patient compliance than daily
injections and this point is relevant considering the need
for long-term treatment [40]. However, we could not evalu-
ate this issue because of the lack of the use of speciﬁc ques-
tionnaires for the assessment of quality of life or adherence
to therapy, which is a limitation of our study. Other limita-
tions of this study may be related to the small size of the pop-
ulation and the short-term follow-up. Indeed, although the
best auxological beneﬁts generally occur during the ﬁrst year
of treatment, a longer follow-up may be useful to have more
reliable data. In addition, data on body composition mea-
sured by dual-energy X-ray absorptiometry as a marker of
metabolic risk might be useful, but they are available for a
minority of patients.
However, the discrepancies among the various studies are
due to the high variability of the patients enrolled (i.e., the
majority of the studies have enrolled children not naïve to
GHT but already treated with GH for a diﬀerent length of
time), to diﬀerent doses of GH used or diﬀerent duration of
the follow-up. To avoid these limits, our study was designed
to enroll only GHD children naïve to GHT and consecutively
admitted in a controlled way. To better understand whether
the two regimens of GHT lead to diﬀerent metabolic out-
comes, we believe that these data must be validated in addi-
tional larger prospective studies with longer follow-up.
Indeed, the duration of 12 months may be probably too short
to fully deﬁne the metabolic impact of the two diﬀerent
modalities of treatment and these data should be considered
as preliminary data.
In conclusion, our study conﬁrmed that GHT with the
TIW injections regimen is eﬀective in improving auxological
parameters and that the auxological eﬃcacy of this regimen is
comparable with that of a daily regimen. This regimen
proved to have at least similar auxological eﬀects to daily
treatment, and it could theoretically ensure higher accep-
tance of treatment in children, in addition to having
6 International Journal of Endocrinology
demonstrated for the ﬁrst time a more favorable metabolic
impact in GHD children. Therefore, the TIW injection regi-
men could represent an eﬀective alternative to the conven-
tional daily regimen during the ﬁrst 1 year of GHT and can
be favorably applied in the treatment of GHD children.
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